Jennifer Kathleen Bielasz

Co-Founder at Arena Pharmaceuticals, Inc.

Jennifer Kathleen Bielasz

Jennifer Kathleen Bielasz

Co-Founder at Arena Pharmaceuticals, Inc.

Overview
Career Highlights

Arena Pharmaceuticals, Inc.

RelSci Relationships

482

Number of Boards

4

Birthday

1963

Age

56

Relationships
RelSci Relationships are individuals Jennifer Kathleen Bielasz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Director & Co-Founder at BIOCOM

Relationship likelihood: Strong

President & Chief Executive Officer at BIOCOM

Relationship likelihood: Strong

Chief Executive Officer at Nabriva Therapeutics Plc

Relationship likelihood: Strong

Chief Executive Officer at Synthetic Genomics, Inc.

Relationship likelihood: Strong

Chairman-Elect at BIOCOM

Relationship likelihood: Strong

Co-President & Chief Executive Officer at GenomeDx Biosciences, Inc.

Relationship likelihood: Strong

Former Interim President & Chief Executive Officer at Intersect ENT, Inc.

Relationship likelihood: Strong

Co-Founder at CARA Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Jennifer Kathleen Bielasz
Potential Connections via
Relationship Science
You
Jennifer Kathleen Bielasz
Co-Founder at Arena Pharmaceuticals, Inc.
Education
B.A.

Rutgers, The State University of New Jersey, is a leading national research university and the state’s preeminent, comprehensive public institution of higher education. Rutgers is dedicated to teaching that meets the highest standards of excellence; to conducting research that breaks new ground; and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. Founded in 1766, Rutgers teaches across the full educational spectrum: preschool to precollege; undergraduate to graduate; postdoctoral fellowships to residencies; and continuing education for professional and personal advancement.

M.S. in Psychology

Lehigh is a premier residential research university, ranked in the top tier of national research universities each year. We are a coeducational, nondenominational, private university that offers a distinct academic environment of undergraduate and graduate students from across the globe. Our university offers majors and programs in four colleges: The College of Arts and Sciences, The College of Business and Economics, The College of Education and The P.C. Rossin College of Engineering and Applied Science. More than 4,700 undergraduate and 2,000 graduate students call Lehigh "home." Located in Pennsylvania’s scenic Lehigh Valley, the campus is in close proximity to both New York City and Philadelphia. Lehigh is comprised of 2,358 acres, making it one of the largest private universities in the country. The Asa Packer Campus, Mountaintop Campus, and Murray H. Goodman Campus are contiguous. In 2012, the university received a Stabler Foundation gift of 755 acres in nearby Upper Saucon Township. Since 1865, generations of students have chosen Lehigh for their educational experience. They know Lehigh is a place where they can make strong personal connections with faculty, conduct research in diverse fields of study, thrive in a dynamic campus community, form lasting bonds with Lehigh alumni, and learn from their own life experiences.

Career History
Co-Founder
1997 - 2016

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Senior Vice President, Corporate Development & Secretary
1989 - 1994

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Director of Business Development & Strategic Planning
1983 - 1989

Part of Grifols SA /Grifols Family/, Alpha Therapeutic Corp. is a company headquartered in Los Angeles, CA. The firm develops of plasma derived products.

Boards & Committees
Chairman, Board of Directors
Prior

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Chairman
Prior

Kværner ASA engages in the provision of engineering, procurement and construction services. It delivers offshore platforms and onshore plants for upstream oil and gas production. Its solutions include steel substructures, topsides, Unmanned Wellhead Platform/Subsea on a Stick, floating structures, decommissioning services, piping technology, front-end development, marine operations, and platform modification and upgrades. The company was founded in 1853 and is headquartered in Lysaker, Norway.

Chairman
Prior

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

Chairman
Prior

BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Jennifer Kathleen Bielasz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Jennifer Kathleen Bielasz's profile does not indicate a business or promotional relationship of any kind between RelSci and Jennifer Kathleen Bielasz.